

# Field Evaluation of a Dual Rapid Immunodiagnostic Test for HIV and Syphilis Infection in Peru

Claire C. Bristow, PhD, MPH, MSc, \* Segundo R. Leon, MT, MT&ID, †† Emily Huang, BS, §  
 Lourdes B. Ramos, BS, † Silver K. Vargas, MPH, † Juan A. Flores, MSc, † Kelika A. Konda, PhD, §  
 Carlos F. Caceres, MD, MPH, PhD, † and Jeffrey D. Klausner, MD, MPH§

**Background:** Integrated prevention for HIV and syphilis is warranted because both syphilis and HIV infections have evidence-based, scalable interventions using current health care mechanisms. The advent of dual rapid point-of-care tests, single devices that can detect multiple infections using the same specimen, provides the opportunity to integrate the screening of syphilis into HIV prevention programs, potentially increasing the numbers of people tested and allowing for same-day testing and treatment. The aim of our study was to evaluate the MedMira Multiplo Rapid TP/HIV Antibody Test (MedMira Inc, Halifax, Nova Scotia, Canada), a qualitative, rapid immunoassay that detects antibodies to *Treponema pallidum* and HIV.

**Methods:** The reference test for comparison to the *T. pallidum* component of the Multiplo TP/HIV Test was the *T. pallidum* particle agglutination assay. For the HIV component, the reference test included a fourth-generation enzyme immunoassay with a confirmatory Western blot test.

**Results:** The sensitivity and specificity for the HIV antibody component were 93.8% (95% confidence interval [CI], 69.8%–99.8%) and 100% (95% CI, 97.7%–100%), respectively. The *T. pallidum* component of the test had a sensitivity of 81.0% (95% CI, 68.1%–94.6%) and a specificity of 100% (95% CI, 97.6%–100%).

**Conclusions:** Our study showed excellent performance of the HIV antibody component of the test and very good performance for the *T. pallidum* antibody component of the MedMira Multiplo Rapid TP/HIV Antibody Test, which should be considered to improve screening coverage. Use of effective dual tests will create improved access to more comprehensive care by integrating the screening of syphilis into HIV prevention programs.

Syphilis and HIV infection continue to present a substantial global public health burden to groups at high risk of infection such as sex workers, men who have sex with men, migrant populations, pregnant women, and other vulnerable populations that are not likely to access traditional testing or health care services.<sup>1,2</sup> Those infections share common risk groups and similar modes of transmission and are often addressed with related strategies. Coinfection is common, and syphilis may increase the risk of HIV acquisition and transmission.<sup>3</sup> A combined antenatal

screening strategy for syphilis and HIV infection, as is recommended by the World Health Organization as part of a comprehensive dual elimination initiative, should be implemented to reduce delays in diagnosis and accelerate entrance into treatment.<sup>4</sup> The advent of dual rapid point-of-care tests, single devices that can detect multiple infections using the same specimen, provides the opportunity to integrate the screening of syphilis into HIV prevention programs, potentially increasing the numbers of people tested and allowing for same-day testing and treatment.<sup>5,6</sup>

Results from multiple laboratory and field evaluations support the very good performance of individual syphilis and HIV rapid point-of-care tests.<sup>7–14</sup> Those test devices use specific antigens that form an antigen-antibody complex when specific antibodies are present in the specimen. The binding of the antibody to the antigen contained in the device produces a visible, colored line that is displayed to indicate a positive result. Use of that technology has been critical in the development of dual rapid tests, which enable the simultaneous diagnosis of multiple infections with a single test. Although dual tests for syphilis and HIV infection are relatively new to the point-of-care test market, recent laboratory evaluations have documented excellent performance for both *Treponema pallidum* and HIV antibody detection in sera and plasma.<sup>15,16</sup> However, there are limited data on the actual performance of dual tests in the field.

The MedMira Multiplo Rapid TP/HIV Antibody Test (MedMira Inc, Halifax, Nova Scotia, Canada) (from here referred to as Multiplo TP/HIV test) is a qualitative, rapid immunoassay that detects antibodies to *T. pallidum* and HIV. The aim of this study was to evaluate the field performance of the MedMira Multiplo Rapid TP/HIV Antibody Test.

## MATERIALS AND METHODS

### Study Population and Study Sites

Participants were identified at outreach sites in Ventanilla, Callao, a port city adjacent to Lima, Peru. Outreach sites were sites frequented by key populations and included a transgender sex worker house and a beauty salon. Participants were recruited through word of mouth and those enrolled included those at high risk for HIV and syphilis infections including sex workers, men who have sex with men, and transgender women older than 18 years and consenting to participate. After obtaining informed consent, a fingerstick whole blood specimen was obtained and a venipuncture whole blood specimen was collected from each participant by a trained phlebotomist.

### Test Under Evaluation

The Multiplo TP/HIV test was conducted on the fingerstick specimen at the site of specimen collection. The Multiplo TP/HIV test is a visually interpreted, immunoassay that qualitatively detects IgM and IgG antibodies to recombinant *T. pallidum* antigens (Tp0171 (TpN15), Tp0435 (TpN17), and Tp0574 (TpN47)), and to HIV-1/2 in human serum, plasma, or whole blood. After

From the \*Division of Global Public Health, Department of Medicine, University of California San Diego, La Jolla, CA; †Unit of Health, Sexual and Human Development, and Laboratory of Sexual Health, Universidad Peruana Cayetano Heredia, Lima, Peru; ‡Department of Global Health, University of Washington, Seattle, WA; §Division of Infectious Disease: Global Health, Department of Medicine, University of California Los Angeles, Los Angeles, CA

Conflict of interest statement: The authors do not have a commercial or other association that might pose a conflict of interest.

Sources of support: This study was funded through a National Institute of Allergy and Infectious Diseases, National Institutes of Health R-01 grant No. 1R01AI099727-01. All test materials were donated by MedMira Inc.

Correspondence: Claire C. Bristow, PhD, MPH, MSc, Division of Global Public Health, UCSD, 9500 Gilman Drive 0507, La Jolla, CA 92093-0507. E-mail: ccbristow@gmail.com.

Received for publication August 7, 2015, and accepted October 10, 2015. DOI: 10.1097/OLQ.0000000000000387

Copyright © 2015 American Sexually Transmitted Diseases Association. All rights reserved.

application of the specimen, a visible line or dot appears if an antigen-antibody-antigen gold particle complex is formed. The test includes a built-in procedural and reagent control line that should always appear if the specimen has been added to the test cartridge and the test reagents are functioning properly. For this study, incomplete control lines were interpreted as invalid tests. The test was read immediately after the solution was absorbed completely, per the manufacturer's instructions. Two readers interpreted the test results separately. In accordance with standard clinical testing protocols in Peru, participants were given syphilis and HIV test results from reference tests within 2 weeks after enrollment. The Multiplo TP/HIV test was investigational, and therefore, the results from the Multiplo TP/HIV test were not reported to participants and were not used for clinical management.

## Reference Standard Tests

Specimens collected by venipuncture were transported to the Laboratory of Sexual Health at the Faculty of Sciences of Universidad Peruana Cayetano Heredia for reference testing. The reference laboratory performed serum separation and comparison testing. The reference test for comparison to the *T. pallidum* component of the Multiplo TP/HIV Test was *T. pallidum* particle agglutination (TPPA; SERODIA-TPPA; Fujirebio Diagnostics, Inc, Japan). In addition, rapid plasma reagin tests (BD Macro-Vue RPR; Becton Dickinson, Franklin Lakes, NJ) were performed on all specimens to assist in clinical diagnosis. For the HIV component comparison, the reference test included a fourth-generation enzyme immunoassay (Genscreen ULTRA HIV Ag-Ab; Bio-Rad, Espoo, France) for the simultaneous qualitative detection of HIV p24 antigen and antibodies to gp41 and gp36 of HIV type 1 (HIV-1 groups M and O) and HIV type 2 (HIV-2). All of the specimens that were positive on the enzyme immunoassay underwent a confirmatory Western blot test (NEW LAV BLOT I; Bio-Rad, Espoo, France).

## Data Analysis

Sensitivity and specificity were estimated and the exact binomial method was used to calculate 95% confidence intervals (CI). Cohen  $\kappa$  statistic was calculated to assess concordance between the test under evaluation and reference tests and to calculate concordance between the 2 test readers. All analyses were conducted using SAS v9.3 (Cary, North Carolina).

## RESULTS

A total of 205 participants were enrolled in the study, 175 (85.4%) had valid Multiplo TP/HIV tests and were included in the analysis. Of the 175, 16 (9.1%) were confirmed as HIV infected based on the reference standard HIV test protocol. One of the 175 specimens had an indeterminate TPPA result and therefore was excluded from the *Treponema* antibody detection component of the analysis. Of the 174 specimens with a TPPA test result, 27 (15.5%) tested positive for the presence of treponemal antibodies based on the reference TPPA test protocol.

The HIV antibody component of the Multiplo test yielded 15 true-positive, 0 false-positive, 1 false-negative, and 159 true-negative results (see Table 1). The sensitivity and specificity for the HIV antibody component were 93.8% (95% CI, 69.8%–99.8%) and 100% (95% CI, 97.7%–100%), respectively. The  $\kappa$  coefficient for HIV antibody between the reference and Multiplo results was 0.97 (95% CI, 0.90–1.00).

The *T. pallidum* antibody component of the test gave 17 true-positive, 0 false-positive, 4 false-negative, and 153 true-negative results (see Table 2). The *T. pallidum* component of the test had a sensitivity of 81.0% (95% CI, 58.1%–94.6%) and a specificity of 100% (95% CI, 97.6%–100%). The  $\kappa$  coefficient for concordance of presence of *T. pallidum* antibodies between the reference and evaluation test was 0.88 (95% CI, 0.77–1.00). Of the 4 *T. pallidum* false-negative results, 1 was rapid plasma reagin reactive.

The Multiplo TP/HIV test results were interpreted separately by 2 readers. All results for the HIV antibody and the *T. pallidum* antibody detection component were concordant between the 2 readers ( $\kappa$  coefficient = 1.00 [95% CI, 1.00–1.00]).

## DISCUSSION

We completed a field evaluation of a dual rapid immunodiagnostic test for HIV and syphilis infection. Our study showed excellent performance of the HIV antibody component of the test and very good performance for the *T. pallidum* antibody component. Those performance findings are consistent with field performance evaluations of single rapid tests for HIV and syphilis antibodies<sup>7–9,11,14,17</sup> and another field study of a dual test.<sup>18</sup> The sensitivity of the *T. pallidum* antibody component of the test was lower than the HIV antibody component. The shape of the color indication of a positive *T. pallidum* result was a circle rather than a line which may be harder to visually identify when the color was faint, which may explain part of the difference in sensitivity. There are various means to potentially increase the sensitivity of rapid tests that could be further evaluated. One useful mechanism is through the use of an electronic reader that has higher optical detection than the human eye.<sup>19</sup> The Multiplo TP/HIV test is an immunofiltration assay rather than a lateral flow assay that is the more well-known assay for a rapid test. The Multiplo test can be read immediately after being inoculated with the specimen and reagents without any wait time, a benefit that is not possible with the lateral flow assay format.

Field evaluations are important to identify the performance characteristics of a test, outside the ideal conditions of a laboratory setting. Rapid point-of-care tests can result in same-day treatment for syphilis and improved linkage to care for HIV infection. In addition, point-of-care tests can be used outside clinical settings and in places with limited laboratory access to improve screening coverage.<sup>7</sup> Multiplex rapid tests provide additional advantages by requiring less equipment and supplies, simplified procurement, and supply chain management, and require only one specimen to test for multiple infections. Furthermore, patients may

**TABLE 1.** Field Performance for Detection of HIV Antibodies Using a Dual HIV/Syphilis Test (n = 205)

	No. Samples		Total	Sensitivity (95% CI)	Specificity (95% CI)	$\kappa$ Coefficient (95% CI)
	Reference test +	Reference test –				
Multiplo Test +	15	0	15	93.8% (69.8%–99.8%)	100% (97.7%–100%)	0.97 (0.90–1.00)
Multiplo Test –	1	159	160			
Total	16	159	175			

Reference testing was conducted with an HIV enzyme immunoassay with a Western blot for confirmation of positive result. Thirty Multiplo tests gave an invalid control line and were excluded from analysis.

**TABLE 2.** Field Performance for Detection of *T. pallidum* Antibodies Using a Dual HIV/Syphilis Test (n = 205)

	No. Samples		Total	Sensitivity (95% CI)	Specificity (95% CI)	$\kappa$ Coefficient (95% CI)
<i>T. pallidum</i> component	Reference test +	Reference test –		81.0% (58.1%–94.6%)	100% (97.6%–100%)	0.88 (0.77–1.00)
Multiplo test +	17	0	17			
Multiplo test –	4	153	157			
Total	21	153	174			

Reference testing was conducted with a TPPA assay. One *T. pallidum* reference test gave an indeterminate and was excluded from analysis. Thirty Multiple tests gave an invalid control line and were excluded from analysis.

also prefer streamlined specimen collection and testing for multiple infections.<sup>20</sup>

This study was subject to some limitations. Firstly, almost 15% of the Multiplo TP/HIV tests gave invalid control lines. Further research should be considered to find ways to improve test controls. However, having a control mechanism within the test allowed us to exclude specimens that may have been inadequately added to the test cartridge or that contained test reagents that were not functioning properly. Another limitation is that findings on the test performance in this setting may vary in other settings, and therefore, this study should be repeated in other sites to assess generalizability. In addition, although field evaluations are essential to understand how a test would perform once rolled out, this study was performed by motivated study staff that may not be representative of the clinical staff that would be responsible for screening. Further research is warranted to determine how a dual test would perform and can be integrated into the flow of a busy sexual health clinic. Another limitation of this study is that we only used one treponemal reference test, which displays high performance but may be an imperfect reference test. We did, however, have access to rapid plasma reagin results which we used to provide some explanation on discordant *T. pallidum* antibody test results. A strength of this study is that we used a fourth-generation HIV antigen-antibody reference test; the fourth-generation tests are the most specific and sensitive enzyme immunoassay tests on the market. Most rapid tests for detection of syphilis, including the Multiplo TP/HIV test, detect treponemal antibodies which can persist for life even after curative treatment. In settings with a high prevalence of syphilis, a confirmatory nontreponemal test, such as the rapid plasma reagin, may be necessary.

HIV and syphilis impact similar risk groups, can both be sexually and perinatally transmitted, and are associated with adverse pregnancy outcomes. The World Health Organization has called for the elimination of mother-to-child of HIV and syphilis infection through a harmonized approach for the improvement of health outcomes for mothers and children.<sup>4</sup> Key populations at risk for HIV and syphilis include sex workers, men who have sex with men, migrant populations, pregnant women, and other vulnerable populations that are not likely to access traditional testing or health care services.<sup>21,22</sup> Those populations often also face substantial barriers to accessing and using traditional health care services and would greatly benefit from the use of rapid point-of-care tests. Our study recruited participants from these key populations in Lima, Peru, to understand how dual testing performs in a population where such testing may be useful. Implementing an accurate, simple, and affordable dual screening strategy for HIV and syphilis could improve case finding and reduce time to treatment.<sup>6</sup> The MedMira Multiplo Rapid TP/HIV Antibody Test should be considered for implementation in settings where both HIV and syphilis testing are needed.

## REFERENCES

1. Newman L. Dual elimination of mother-to-child transmission (MTCT) of HIV and syphilis. Training course in sexual and reproductive health

- research. Available at: <http://www.gfmer.ch/SRH-Course-2013/sti/pdf/Dual-EMTCT-HIV-syphilis-Newman-2013.pdf>. 2013.
2. UNAIDS. Global report: UNAIDS report on the global AIDS epidemic 2013. Available at: [http://www.unaids.org/sites/default/files/media\\_asset/UNAIDS\\_Global\\_Report\\_2013\\_en\\_1.pdf](http://www.unaids.org/sites/default/files/media_asset/UNAIDS_Global_Report_2013_en_1.pdf). 2013. Accessed September 18, 2014.
3. Sanchez J, Lama JR, Peinado J, et al. High HIV and ulcerative sexually transmitted infection incidence estimates among men who have sex with men in Peru: Awaiting for an effective preventive intervention. *J Acquir Immune Defic Syndr* 2009; 51(suppl 1):S47–S51.
4. WHO. Elimination of mother-to-child transmission (EMTCT) of HIV and syphilis: Global guidance on criteria and processes for validation. Available at: <http://www.who.int/reproductivehealth/publications/rtis/9789241505888/en/>. 2014.
5. Dinh TH, Kamb ML, Msimang V, et al. Integration of preventing mother-to-child transmission of HIV and syphilis testing and treatment in antenatal care services in the Northern Cape and Gauteng provinces, South Africa. *Sex Transm Dis* 2013; 40:846–851.
6. Klausner JD. The sound of silence: missing the opportunity to save lives at birth. *Bull World Health Organ* 2013; 91:158–158A.
7. Benzaken AS, Sabidó M, Galban E, et al. Field performance of a rapid point-of-care diagnostic test for antenatal syphilis screening in the Amazon region, Brazil. *Int J STD AIDS* 2011; 22:15–18.
8. Bergman J, Gratrix J, Plitt S, et al. Feasibility and field performance of a simultaneous syphilis and HIV point-of-care test based screening strategy in at risk populations in Edmonton, Canada. *AIDS Res Treat* 2013; 2013:819593.
9. Kagulire SC, Opendi P, Stamper PD, et al. Field evaluation of five rapid diagnostic tests for screening of HIV-1 infections in rural Rakai, Uganda. *Int J STD AIDS* 2011; 22:308–309.
10. Montoya PJ, Lukehart SA, Brentlinger PE, et al. Comparison of the diagnostic accuracy of a rapid immunochromatographic test and the rapid plasma reagin test for antenatal syphilis screening in Mozambique. *Bull World Health Organ* 2006; 84:97–104.
11. Nessa K, Alam A, Chawdhury FA, et al. Field evaluation of simple rapid tests in the diagnosis of syphilis. *Int J STD AIDS* 2008; 19: 316–320.
12. Tucker JD, Bu J, Brown LB, et al. Accelerating worldwide syphilis screening through rapid testing: A systematic review. *Lancet Infect Dis* 2010; 10:381–386.
13. Tucker JD, Bien CH, Peeling RW. Point-of-care testing for sexually transmitted infections: Recent advances and implications for disease control. *Curr Opin Infect Dis* 2013; 26:73–79.
14. West B, Walraven G, Morison L, et al. Performance of the rapid plasma reagin and the rapid syphilis screening tests in the diagnosis of syphilis in field conditions in rural Africa. *Sex Transm Infect* 2002; 78:282–285.
15. Bristow CC, Adu-Sarkodie Y, Ondo RO, et al. Multisite laboratory evaluation of a dual human immunodeficiency virus (HIV)/syphilis point-of-care rapid test for simultaneous detection of HIV and syphilis infection. *Open Forum Infect Dis* 2014; 1:ofu015.
16. Esfandiari J, Gunasekera D, Sayegh F, et al. Performance evaluation of the Chembio DPP® HIV-Syphilis Assay: A novel, point-of-care rapid HIV 1/2 and syphilis. Abstract presented at: 2012 HIV Diagnostics Conference 2012; 12 December 2012; Atlanta, GA. Available at: <https://custom.cvent.com/ADE0EB81B3184D618E2FB8340F1EC28E/files/29f371770a44f91859f65feb4cefec6.pdf>.
17. Strasser S, Bitarakwate E, Gill M, et al. Introduction of rapid syphilis testing within prevention of mother-to-child transmission of HIV programs in Uganda and Zambia: A field acceptability and feasibility study. *J Acquir Immune Defic Syndr* 2012; 61:e40–e46.

18. Bristow CC, Leon S, Ramos Cordova L, et al. Clinical evaluation of a dual rapid diagnostic test for HIV and syphilis, SD Bioline HIV/syphilis Duo, Lima, Peru. Available at: <http://www.cdc.gov/stdconference/2014/2014-std-prevention-conference-abstracts.pdf>. CDC STD Prevention Conference, Atlanta, GA 2014.
19. Mudanyali O, Dimitrov S, Sikora U, et al. Integrated rapid-diagnostic-test reader platform on a cellphone. *Lab Chip* 2012; 12:2678–2686.
20. Bristow CC, Lee SJ, Leon S, et al. Assessing factors to increase uptake of testing for syphilis and HIV in men who have sex with men and transgender women in Lima, Peru. 2013. CDC STD Prevention Conference, Atlanta, GA. Available at: <http://www.cdc.gov/stdconference/2014/2014-std-prevention-conference-abstracts.pdf>. 2014.
21. Gardner EM, McLees MP, Steiner JF, et al. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. *Clin Infect Dis* 2011; 52:793–800.
22. Geibel S, Tun W, Tapsoba P, et al. HIV vulnerability of men who have sex with men in developing countries: Horizons studies, 2001–2008. *Public Health Rep* 2010; 125:316–324.